Show simple item record

dc.contributor.authorUltsch, Bernhard
dc.contributor.authorKöster, Ingrid
dc.contributor.authorReinhold, Thomas
dc.contributor.authorSiedler, Anette
dc.contributor.authorKrause, Gerard
dc.contributor.authorIcks, Andrea
dc.contributor.authorSchubert, Ingrid
dc.contributor.authorWichmann, Ole
dc.date.accessioned2014-06-12T14:54:07Zen
dc.date.available2014-06-12T14:54:07Zen
dc.date.issued2013-12en
dc.identifier.citationEpidemiology and cost of herpes zoster and postherpetic neuralgia in Germany. 2013, 14 (6):1015-26 Eur J Health Econen
dc.identifier.issn1618-7601en
dc.identifier.pmid23271349en
dc.identifier.doi10.1007/s10198-012-0452-1en
dc.identifier.urihttp://hdl.handle.net/10033/321307en
dc.description.abstractAfter acquiring a varicella virus infection, the virus can reactivate and cause herpes zoster (HZ)--a painful skin rash. A complication of HZ is long-term persistence of pain after the rash has resolved (so-called postherpetic neuralgia, PHN). We aimed to describe the epidemiology of HZ/PHN and to estimate HZ/PHN-related costs in the German statutory health insurance (SHI) system (~85% of the total population). Treatment data of one large SHI was utilized, containing data on approximately 240,000 insured and their utilisation of services in 2004-2009. Identification of HZ- and PHN-cases was performed based on 'International Statistical Classification of Diseases' and specific medications using a control-group design. Incidences per 1,000 person-years (PY) and cost-of-illness for 1 year following HZ-onset considering the payer and societal perspective were calculated. All amounts were inflated to 2010 Euros. Population-figures were standardised and extrapolated to the total SHI-population in Germany in 2010. A mean annual incidence of 5.79 HZ-cases per 1,000 PY was observed, translating into an estimated 403,625 HZ-cases per year in the total SHI-population. Approximately 5% of HZ-cases developed PHN. One HZ-case caused on average euro 210 and euro 376 of costs from the payer and societal perspective, respectively. The development of PHN generated additional costs of euro 1,123 (euro 1,645 societal perspective). Total annual HZ/PHN-related costs were estimated at euro 182 million (euro 105 million) to society (payer). HZ and PHN place a considerable burden on the German SHI-system. Since HZ-vaccines will soon be available, a health-economic evaluation of these vaccines should be conducted.
dc.language.isoenen
dc.rightsArchived with thanks to The European journal of health economics : HEPAC : health economics in prevention and careen
dc.titleEpidemiology and cost of herpes zoster and postherpetic neuralgia in Germany.en
dc.typeArticleen
dc.contributor.departmentEpidemiology, Helmholtz Centre for infection research, Inhoffenstr. 7, 38124 Braunschweig, Germany.en
dc.identifier.journalThe European journal of health economics : HEPAC : health economics in prevention and careen
refterms.dateFOA2018-06-13T02:40:38Z
html.description.abstractAfter acquiring a varicella virus infection, the virus can reactivate and cause herpes zoster (HZ)--a painful skin rash. A complication of HZ is long-term persistence of pain after the rash has resolved (so-called postherpetic neuralgia, PHN). We aimed to describe the epidemiology of HZ/PHN and to estimate HZ/PHN-related costs in the German statutory health insurance (SHI) system (~85% of the total population). Treatment data of one large SHI was utilized, containing data on approximately 240,000 insured and their utilisation of services in 2004-2009. Identification of HZ- and PHN-cases was performed based on 'International Statistical Classification of Diseases' and specific medications using a control-group design. Incidences per 1,000 person-years (PY) and cost-of-illness for 1 year following HZ-onset considering the payer and societal perspective were calculated. All amounts were inflated to 2010 Euros. Population-figures were standardised and extrapolated to the total SHI-population in Germany in 2010. A mean annual incidence of 5.79 HZ-cases per 1,000 PY was observed, translating into an estimated 403,625 HZ-cases per year in the total SHI-population. Approximately 5% of HZ-cases developed PHN. One HZ-case caused on average euro 210 and euro 376 of costs from the payer and societal perspective, respectively. The development of PHN generated additional costs of euro 1,123 (euro 1,645 societal perspective). Total annual HZ/PHN-related costs were estimated at euro 182 million (euro 105 million) to society (payer). HZ and PHN place a considerable burden on the German SHI-system. Since HZ-vaccines will soon be available, a health-economic evaluation of these vaccines should be conducted.


Files in this item

Thumbnail
Name:
Ultsch et al_final.pdf
Size:
361.8Kb
Format:
PDF
Description:
original manuscript

This item appears in the following Collection(s)

Show simple item record